Iotrolan
From Wikipedia, the free encyclopedia
 |
The introduction to this article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. |
 |
|
|
Iotrolan
|
|
| Systematic (IUPAC) name | |
| 2,4,6-Triiodo-5-[methyl-[3-[methyl-[2,4,6-triiodo-3,5-bis(1,3,4-trihydroxybutan-2-ylcarbamoyl)phenyl]amino]-3-oxopropanoyl]amino]-N,N'-bis(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C37H48I6N6O18 |
| Mol. mass | 1626.23 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Iotrolan (brand name Isovist) is a dimer of triiodinated isophthalic acid derivatives, used as a radiocontrast agent. It is particularly used to image spaces surrounding the central nervous system, such as the ventricles, after injection into the cerebrospinal fluid. It can also be used to image joint spaces and in endoscopic retrograde cholangiopancreatography (ERCP).
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
